Clinical Trials Logo

Clinical Trial Summary

Maternal obesity (MO) affects 1 in 5 women and is strongly linked to increased birth weight, childhood/adolescent obesity, life-long metabolic and inflammatory disorders, and childhood neuropsychiatric disorders. There remains a critical unmet need for developing a safe and effective non-pharmacological approach for attenuating metabolic inflammation and ameliorating the adverse effects of MO on offspring health that originate in utero and extend into the lactational period. Pyrroloquinoline quinone (PQQ) is a diet-derived natural food supplement with anti-inflammatory properties that, in humans and mice, improves metabolism and exerts potent immunoregulatory effects. Researchers' central hypothesis is that PQQ administration during MO pregnancy 1) improves maternal metabolic and inflammatory indices, 2) improves utero-placental blood flow and ameliorates placental maladaptation (oxidative stress, hypoxia, inflammation and fatty acid transporter expression) and 3) reduces neonatal adiposity.


Clinical Trial Description

Women with a body mass index (BMI) greater than 30 will be recruited during their first trimester clinic visit up to 16 weeks of gestation. In addition to the blood draw and anthropometric measurements normally carried out at the first pre-natal visit, researchers will provide consented study subjects with pyrroloquinoline quinone (PQQ) or placebo in capsules at a dose of 20 milligrams per day. There will be 15 women per group. At ~30 days after initiating the study (4-week routine follow-up visit) blood samples will be obtained. At ~24-28 weeks gestation, during the 2nd trimester visit, study subjects will undergo the standard 1-hour oral glucose screen, routine prenatal complete blood count (CBC) evaluation, study maternal blood sampling, and anthropometric measurements. During the delivery inpatient admission, researchers will again collect maternal blood as well as placental tissue, and umbilical cord blood (plasma, aperipheral blood mononuclear cells) after delivery. Placental tissue (samples from four separate cotyledons) will be collected for protein (homogenate and plasma membrane isolation), ribonucleic acid (RNA), quantitative polymerase chain reaction (qPCR), and histology (fixed in 4% paraformaldehyde). The neonate will undergo PeaPod evaluation prior to discharge, and within 72 hours after birth. PQQ supplementation will continue for 30 days post-partum at which time maternal blood and breastmilk samples will be collected, as well as a follow up infant Peapod evaluation and maternal dual x-ray absorptiometry (DEXA) scan. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT06245083
Study type Interventional
Source University of Oklahoma
Contact Marta Maxted, MD
Phone 4052715597
Email marta-maxted@ouhsc.edu
Status Not yet recruiting
Phase Early Phase 1
Start date May 2024
Completion date April 2025

See also
  Status Clinical Trial Phase
Completed NCT00530439 - Lifestyle and Pregnancy: The Clinical Effect of Lifestyle Intervention During Pregnancy in Obese Women N/A
Recruiting NCT03084120 - Effect of the Maternal Obesity and/or the By-pass on the Growth and the Nutritional Balance of the Child N/A
Recruiting NCT05207059 - Healthy Early Life Moments in Singapore N/A
Terminated NCT03435458 - Balloon to Induce Labor in Generous Women. Phase 3
Not yet recruiting NCT03913364 - Impact of B. Bifidum 900791 Intake on Breast Milk Characteristics of Obese Mothers N/A
Not yet recruiting NCT05986539 - Early Life Feeding Exposure and Infant Immune and Health Status.
Not yet recruiting NCT06179381 - Feeding the fAmiLy: the Intergenerational approaCh to fIght obesiTY (FACILITY)
Completed NCT05475951 - Gasdermin-D and Pannexin-1 in Pregnancy N/A
Active, not recruiting NCT04060381 - Myocardial Deformation Before and After Birth